FDA in the Shutdown: Drug Center Stays Open (Mostly); Ben Venue Does Not
This article was originally published in RPM Report
Executive Summary
New drug approvals continued during the partial government shutdown, as user fees helped keep most of the FDA review functions running smoothly. The drug center did face some unusual challenges, including responding to a major manufacturing shutdown (by Ben Venue) – and to speculation about a leadership change at the drug center.